Product Description
For restoring penile erections in patients with erectile dysfunction
Mechanisms of Action: CRFR Antagonist
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Erectile Dysfunction
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2005-004648-30 | P2 |
Completed |
Erectile Dysfunction |
2006-06-29 |
2022-03-12 |
Treatments |
|
| A7771002 | P2 |
Completed |
Erectile Dysfunction |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|